What I am working with: semaglutide · twelve weeks.
I want to decide this in advance so that I am not deciding it under pressure later.
Assume I will follow the plan I write down, so I would like it to be a good one.
How would you structure this, and what thresholds would you set in advance?
12 weeks is 84 days: 12 weekly administrations, and 3 four-week dose steps. Two draws fit inside that span honestly — baseline before the first dose, one repeat — plus a written trigger for anything extra. A third is a budget rather than a plan at 12 weeks. The constraint is that the markers worth drawing move more slowly than 84 days. An HbA1c integrates roughly the preceding ninety days, so a repeat at day 84 is still about 7 per cent pre-treatment blood and mostly reports where you started. Lipids and hepatic enzymes settle faster and are worth the repeat at 84 days. A renal panel earns its place at baseline specifically so that an early eGFR change has something to be a change from. Fix the repeat date at the start, in writing. A monitoring plan decided after a result arrives is not a plan, and nothing here is medical advice.
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Decide the action for each result before you order the test.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Worth being precise here: delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 18 Jun 2025 by grainne_ahearn — expanded the table to cover the lower concentration
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Keep the full report, not the number. You will need the units and the interval later.
The part that matters: this is answerable, and the answer is mostly about which tests rather than how many.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
SELECT reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for the primary composite major adverse cardiovascular event endpoint with semaglutide 2.4 mg in overweight or obese adults with established cardiovascular disease and without diabetes[1].
Research-use compounds are not approved for human use, and no panel makes that safer.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.